At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Rana McKay, Professor of Medicine and Urology at UC San Diego Health and Co-leader of the GU Oncology Program at Moores Cancer Center, delivered a talk on “Future Directions: Emerging Agents and Combinations”.
She highlighted how RCC innovation is clustering around HIF/VEGF pathway inhibition and smart combinations—while antibody–drug conjugates and radioligands remain promising but early.
She also discussed belzutifan, a HIF-2α inhibitor, and its integration into combinations with cabozantinib, pembrolizumab, and lenvatinib, showing durable responses and prolonged progression-free survival across both treatment-naïve and pretreated cohorts. Next-generation HIF-2α inhibitors like casdatifan are advancing in phase 3 studies, with the potential to further refine outcomes in RCC.
Join us in this conversation.